
Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease
Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease
Details
More Products & Services
People

Kimberly Sweeney
Roswell Park Comprehensive Cancer Center
Vice President of Patient Experience

Sai Yendamuri
Roswell Park Comprehensive Cancer Center
Chief Strategy Officer; SVP of Business Development & Outreach; Chair of Thoracic Surgery

Shashi Lele
Roswell Park Comprehensive Cancer Center
Medical Director, International Patients

Sunita Panesar
Roswell Park Comprehensive Cancer Center
Vice President of Strategy, Business Development & Outreach
Description
HIGHLIGHTS:
- Study added pacritinib to standard sirolimus/tacrolimus regimen
- JAK2 inhibition + reducing Th1/Th17 cells does not improve GVHD prevention
- Results published in Blood, the leading hematology journal
- Study added pacritinib to standard sirolimus/tacrolimus regimen
- JAK2 inhibition + reducing Th1/Th17 cells does not improve GVHD prevention
- Results published in Blood, the leading hematology journal

Share
Recent Chats
Share via email
Future: handle WhatsApp here
Future: handle LinkedIn here
Future: handle Twitter here
SUBMENU HERE
Share via Chat
Copy Link